CENPA fusion antigen as well as preparation method and application thereof
By fusing CENPA protein fragments with histone fragments and expressing them in insect cells, the problems of low expression and low detection sensitivity in existing CENPA antibody detection methods are solved, and higher detection specificity and sensitivity are achieved. for the diagnosis of systemic sclerosis.
Patent Information
- Application Number
- CN202411015661.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-26
AI Technical Summary
The existing CENPA antibody detection methods have problems with low expression, high hydrophobicity and low detection sensitivity, and it is difficult to effectively recognize CENPA antibodies.
By fusing CENPA protein fragments with histone fragments, the stability and biological activity of the fusion proteins are improved by connecting peptides and signal peptides, and expressed in insect cells, combining His tags for isolation and purification, forming CENPA fusion antigens.
It improves the specificity and sensitivity of CENPA antibody detection, achieves soluble expression and efficient secretion in insect cells, and has good application prospects for the diagnosis of systemic sclerosis.
Smart Images

Figure CN118955676A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a CENPA fusion antigen and a preparation method and application thereof. Background Art
[0002] Centromere proteins are a class of proteins that form or regulate centromere function. The central structure of chromosomes is attached with spindle fibers and tubulin, which allows chromosomes to separate during cell division. Currently, there are 9 known centromere proteins, most of which are targets of autoantibodies and anti-centromere antibodies. CENPA (Centromere protein A, CENPA) is another important centromere autoantigen besides CENPB. Its molecular weight is close to 22kDa, and it has histone-like properties. It forms a polymer structure with histones H3 and H4 and participates in the formation of centromere chromatin.
[0003] Systemic Sclerosis (SSc) is a systemic disorder of connective tissue, characterized by peripheral arterial atherosclerosis and visceral structural fibrosis, which can lead to fibrosis and functional decline of the heart, lungs, kidneys, and gastrointestinal tract. Systemic Sclerosis (SSc) is often associated with specific autoimmune antibodies, of which centromere antibodies are an important type of autoimmune antibodies. Therefore, the detection of CENPA antibodies plays an important role in the auxiliary diagnosis of SSc.
[0004] Currently, the detection of CENPA antibodies is mainly carried out through immunodiagnosis: CENPA protein fixed on the carrier can specifically bind to CENPA antibodies, and further through the labeled antibody to recognize the fixed CENPA antibodies, the detection of CENPA antibodies is achieved. However, recombinant CENPA protein has a series of problems such as low expression level, high hydrophobicity and low detection sensitivity.
[0005] Therefore, it is urgent to discover antigens that have good CENPA antibody recognition function and can be effectively used in CENPA antibody detection.
[0006] In view of this, the present invention is proposed. Summary of the invention
[0007] The object of the present invention is to provide a CENPA fusion antigen and a preparation method and application thereof. The CENPA fusion antigen has higher detection specificity and sensitivity than the CENPA protein.
[0008] The present invention is achieved in that:
[0009] According to one aspect of the present invention, the present invention provides a CENPA fusion antigen, wherein the CENPA fusion antigen contains a CENPA protein fragment and a histone fragment.
[0010] The amino acid sequence of the CENPA protein fragment is preferably as shown in SEQ ID NO.3.
[0011] The histone fragment in the CENPA fusion antigen provided by the present invention is derived from histone H3 or histone H4, the histone H3 amino acid sequence is shown in SEQ ID NO.4, and the histone H4 amino acid sequence is shown in SEQ ID NO.5.
[0012] The histone can be connected to the C-terminus or N-terminus of CENPA. In some preferred embodiments, the CENPA protein fragment is fused to the N-terminus of the histone fragment. In a more preferred embodiment, the CENPA protein fragment and the histone fragment are connected via a first connecting peptide. The connecting peptide can improve the stability, expression amount and biological activity of the fusion protein. The amino acid sequence of the first connecting peptide of the present invention is shown in SEQ ID NO.6.
[0013] In some preferred embodiments, the CENPA fusion protein further contains a signal peptide, which enables the recombinant antigen to be effectively secreted and expressed in insect cells. The signal peptide is preferably a GP67 signal peptide, whose amino acid sequence is shown in SEQ ID NO.8, and the signal peptide is connected to the N-terminus of the fusion protein fragment.
[0014] In some preferred embodiments, the CENPA fusion protein further contains a tag, which is used for the separation and purification of the CENPA fusion protein. The tag can be a conventional protein tag in the art, and the tag can be added to the amino terminus and / or carboxyl terminus of the CENPA fusion protein. The present invention selects a His tag (HHHHHH, SEQ ID NO.7), which can be used with Ni + The His tag is preferably connected to the C-terminus of the CENPA fusion protein.
[0015] In some preferred embodiments, the histone fragment and the His tag are connected by a second connecting peptide, which is more conducive to tag display. From the N-terminus to the C-terminus, there are a signal peptide, a CENPA protein fragment, a first connecting peptide, a histone fragment, a second connecting peptide and a His tag. The sequences of the first connecting peptide and the second connecting peptide can be the same or different. In some preferred embodiments, the sequence of the second connecting peptide is: SGG.
[0016] The amino acid sequence of the CENPA fusion protein having the above structure after expression is preferably the sequence shown in SEQ ID NO.1 or SEQ ID NO.2, which has better antigenicity and can be expressed soluble in insect cells.
[0017] According to another aspect of the present invention, the present invention also provides a gene encoding the above-mentioned CENPA fusion protein. The gene is preferably a sequence as shown in SEQ ID NO.9 or SEQ ID NO.10, or a sequence with more than 90% homology to the sequence shown in SEQ ID NO.9 or SEQ ID NO.10. A sequence with more than 90% homology to the sequence shown in SEQ ID NO.9 or SEQ ID NO.10 refers to a nucleic acid sequence that has a certain difference from the sequence shown in SEQ ID NO.9 or SEQ ID NO.10 due to the deletion, mutation, reduction or addition of nucleotides, but is at least 90% similar and has the same function. The homology can be, for example, but not limited to, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
[0018] According to another aspect of the present invention, the present invention also provides a biomaterial, which includes at least one of a polynucleotide, an expression cassette, a vector, a recombinant microorganism or a cell line. The biomaterial can express a CENPA fusion protein and / or contains a gene encoding a CENPA fusion protein. The biomaterial is, for example, a gene encoding a CENPA fusion protein; an expression cassette containing the gene encoding the CENPA fusion protein; or, for example, a vector containing a gene encoding a CENPA fusion protein, so that the gene encoding the CENPA fusion protein can be replicated or expressed in a host, or the gene can be integrated into a medium in a host cell, and examples of vectors include but are not limited to plasmids, phagemids, phages and viral genomes. The biomaterial can also be a recombinant microorganism, which contains a vector encoding a gene encoding a CENPA fusion protein, and the gene can be cloned in a microorganism to increase the copy number of the gene. The biomaterial can also be a cell line, which contains an expression vector of a gene encoding a CENPA fusion protein, and the cell line can express a CENPA fusion protein.
[0019] According to another aspect of the present invention, the present invention also provides a method for preparing a CENPA fusion protein, the method comprising expressing a gene encoding the CENPA fusion protein in a host. The method is simple to operate and is suitable for large-scale production of CENPA fusion protein.
[0020] According to another aspect of the present invention, the present invention also provides a polypeptide conjugate, which includes the above-mentioned CENPA fusion antigen and a conjugate connected thereto. The conjugate includes a solid phase carrier. Preferably, the solid phase carrier is selected from any one of magnetic particles, plates and membranes. More preferably, the solid phase carrier is a magnetic particle.
[0021] According to another aspect of the present invention, the present invention also provides the use of CENPA fusion antigen, biological material or polypeptide conjugate in preparing a product for detecting CENPA antibody.
[0022] According to another aspect of the present invention, the present invention also provides a kit, which comprises at least one of a CENPA fusion antigen, a biological material and a polypeptide conjugate.
[0023] In some embodiments, the kit comprises a CENPA fusion antigen for detecting CENPA antibodies. The kit may optionally be an ELISA kit, and thus the kit may further comprise reagents and consumables for conducting ELISA experiments.
[0024] According to another aspect of the present invention, a method for detecting CENPA antibodies for non-diagnostic purposes is provided, comprising: contacting a sample to be tested with a CENPA fusion antigen coated on a solid phase carrier, and identifying the CENPA antibodies captured by the CENPA fusion antigen by a labeled antibody.
[0025] The present invention has the following beneficial effects:
[0026] The CENPA fusion antigen of the present invention is formed by connecting a CENPA protein fragment and a histone fragment. Compared with single CENPA, the CENPA fusion antigen has better antigenicity and better effect in detecting scleroderma. At the same time, the fusion protein of the present invention can be expressed in insect cells in a secretory form. The fusion protein has good hydrophilicity and can be effectively applied to CENPA antibody detection. Therefore, the CENPA fusion antigen of the present invention has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0028] Figure 1 This is the SDS-PAGE image of CENPA_H3 protein in Example 1 of the present invention;
[0029] Figure 2This is the SDS-PAGE image of CENPA_H4 protein in Example 1 of the present invention. DETAILED DESCRIPTION
[0030] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0031] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0032] Example 1
[0033] The present invention is a method for preparing a fusion protein, comprising the following steps:
[0034] (1) Construction of fusion protein expression vector:
[0035] A gene fragment including a fusion protein as described in SEQ ID NO.1 or 2 (with a signal peptide GP67 as shown in SEQ ID NO.8 at the N-terminus) is obtained by gene synthesis, and the nucleotide sequence of the gene fragment is as shown in SEQ ID NO.9 or 10. The above gene fragment is inserted between the BamHI and HindIII sites of the vector pFastBac1 by common molecular biological methods (including PCR, enzyme ligation, etc.) to construct expression vectors GP67-CENPA_H3-6histag and GP67-CENPA_H4-6histag.
[0036] The above expression vector was transformed into E. coli DH10Bac competent cells and cultured on LB agar plates. Positive colonies were picked for colony PCR verification. After verification, the culture was expanded and the corresponding BacmidDNA was extracted.
[0037] (2) Expression and purification of fusion protein:
[0038] The sf9 cells were transfected with the above-mentioned Bacmid DNA, cultured at 27°C for 4 h, and then the culture medium was replaced. After further culture for 5 days, the supernatant was collected by centrifugation, which was the P1 generation virus.
[0039] The P1 virus was re-infected in Sf9 cells, and the cells were cultured at 27°C and 100 rpm in the dark. After 4 days of culture, the supernatant was collected by centrifugation, which was the P2 virus.
[0040] The P2 virus solution infected High Five cells, cultured at 27°C in the dark, with a rotation speed of 100 rpm / min; after 48 hours of culture after infection, the culture supernatant was collected by centrifugation, and the target protein was purified using a Ni column - the supernatant was added to a Ni Resin affinity chromatography column (NiHiTrap column), eluted with 50mM, 100mM, 200mM and 500mM imidazole solutions, respectively, and the elution peaks were collected.
[0041] (3) Ion exchange chromatography:
[0042] The eluted peak was added to the Q HiTrap column, washed with low salt buffer for 10 CV, and then eluted and collected with high salt. The obtained protein was verified by SDS-PAGE.
[0043] In this example, two high-purity target fusion proteins were prepared: CENPA_H3 and CENPA_H4. Figure 1 This is the SDS-PAGE image of CENPA_H3 protein. Figure 2 This is the SDS-PAGE image of CENPA_H4 protein.
[0044] Experimental Example 1
[0045] This experiment is a comparison of the fusion proteins CENPA_H3 and CENPA_H4.
[0046] The fusion proteins CENPA_H3 and CENPA_H4 prepared in Example 1 were coated on Elisa plates respectively, and then IgG labeled with fluorescein phycoerythrin (PE) was used as a secondary detection antibody to detect 10 SSC-positive serum samples.
[0047] The corresponding fluorescence values were detected under the fluorescence reader, and the antigenicity of the two fusion proteins was determined according to the fluorescence cutoff value (the cutoff value was 1000, that is, a reaction value > 1000 was judged as positive, and a reaction value < 1000 was judged as a missed case of the antigen). The evaluation results are shown in Table 1.
[0048] Table 1 Evaluation results of CENPA_H3 and CENPA_H4
[0049]
[0050]
[0051] As can be seen from Table 1, for 10 SSC-positive serum samples, the detection sensitivity of CENPA_H3 was 100% (10 / 10), and the detection sensitivity of CENPA_H4 was 80% (8 / 10), and the reaction value of CENPA_H3 was 28.1% higher than that of CENPA_H4 on average. Therefore, the antigenicity of the recombinant protein CENPA_H3 is significantly better than that of CENPA_H4.
[0052] Experimental Example 2
[0053] This experiment is to verify the performance of fusion antigen
[0054] Using CENPA (amino acid sequence as shown in SEQ ID NO. 11) as a control, the detection results of the fusion proteins CENPA_H4 (prepared in Example 1) and CENPA_H3 (prepared in Example 1) were verified.
[0055] The evaluation method is as follows: CENPA, fusion proteins CENPA_H4, and CENPA_H3 were coated on Elisa plates respectively, and then IgG labeled with fluorescein phycoerythrin (PE) was used as the secondary detection antibody to detect the conditions of 47 serum samples (including 25 SSC-positive samples and 22 SSC-negative samples).
[0056] The corresponding fluorescence value was detected under the fluorescence reader, and the positive and negative were determined according to the fluorescence cutoff value (the cutoff value was 1000, that is, the reaction value > 1000 was judged as positive, and the reaction value < 1000 was judged as negative). The verification results are shown in Tables 2 and 3 below.
[0057] Table 2. Verification results of positive samples
[0058] Positive sample number CENPA response value Reaction value of CENPA_H4 Reaction value of CENPA_H3 1 14847 19247 24570 2 20036 17468 18475 3 22350 28463 32584 4 12375 14863 28438 5 812 895 956 6 21068 31473 38573 7 9842 97134 12583 8 1420 1256 3841 9 2873 3586 4532 10 12052 16453 21490 11 703 946 1190 12 10830 16210 24162 13 8455 8627 9832 14 460 753 856 15 12823 19432 24831 16 16217 25438 30599 17 916 1248 1521 18 1230 1127 1638 19 11916 20736 28754 20 20762 39867 44133 21 15838 34153 35382 22 821 968 1687 23 2185 3654 4419 24 1939 1843 4083 25 12470 17543 18354
[0059] Table 3 Negative sample verification results
[0060] Negative sample number CENPA response value Reaction value of CENPA_H4 Reaction value of CENPA_H3 1 711 743 785 2 265 565 664 3 823 834 778 4 718 810 521 5 815 756 724 6 498 583 644 7 720 712 815 8 1120 1038 958 9 523 653 716 10 463 653 724 11 396 381 528 12 453 589 621 13 1356 1510 1619 14 820 931 923 15 412 598 694 16 721 754 672 17 532 643 685 18 550 673 645 19 264 368 469 20 222 297 394 21 632 674 589 22 512 641 680
[0061] The verification results of positive samples and negative samples are statistically analyzed, and the statistical results are as follows:
[0062] Table 4 Verification results statistics
[0063]
[0064]
[0065] As shown in Table 4, the sensitivity of CENPA_H3 and CENPA_H4 is better than that of CENPA. Among them, the detection sensitivity of CENPA_H3 is 92.0%, which is significantly higher than the 80.0% of single CENPA; the detection specificity of CENPA_H3 is also increased from 90.9% of single CENPA to 95.5%. In summary, the fusion antigens CENPA_H3 and CENPA_H4 can replace CENPA for the diagnosis of systemic sclerosis, and CENPA_H3 is the best.
[0066] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A CENPA fusion antigen, characterized in that: Contains CENPA protein fragments and histone fragments; the histones include any one of histone H3 and histone H4.
2. The CENPA fusion antigen according to claim 1, characterized in that: The amino acid sequence of the CENPA protein fragment is shown in SEQ ID NO.3; Preferably, the amino acid sequence of the histone H3 is as shown in SEQ ID NO.4; Preferably, the amino acid sequence of the histone H4 is as shown in SEQ ID NO.5; Preferably, the histone is linked to the C-terminus of the CENPA protein fragment; Preferably, the CENPA protein fragment is connected to the histone via a first connecting peptide; Preferably, the amino acids of the first connecting peptide are as shown in SEQ ID NO.
6.
3. The CENPA fusion antigen according to claim 1, characterized in that: The CENPA fusion antigen also contains a tag; Preferably, the tag comprises a His tag; Preferably, the tag is connected to the C-terminus of the CENPA fusion antigen; Preferably, the tag is connected to the C-terminus of the CENPA fusion antigen via a second connecting peptide; Preferably, the amino acid sequence of the CENPA fusion antigen is as shown in SEQ ID NO.1; Preferably, the amino acid sequence of the CENPA fusion antigen is as shown in SEQ ID NO.
2.
4. The CENPA fusion antigen according to any one of claims 1 to 3, characterized in that: The CENPA fusion antigen also contains a signal peptide; Preferably, the signal peptide comprises a GP67 signal peptide, and the signal peptide is located at the N-terminus of the fusion antigen; Preferably, the amino acid sequence of the signal peptide is as shown in SEQ ID NO.
8.
5. A biological material, comprising at least one of a polynucleotide, an expression cassette, a vector, a recombinant microorganism or a cell line; The polynucleotide encodes the CENPA fusion antigen according to any one of claims 1 to 4; The expression cassette, vector, recombinant microorganism or cell line carries the polynucleotide.
6. The method for preparing the CENPA fusion antigen according to any one of claims 1 to 4, characterized in that: include: Expressing the CENPA fusion antigen in a host cell; Preferably, the host cell is an insect cell.
7. A polypeptide conjugate, characterized in that: Comprising the CENPA fusion antigen according to any one of claims 1 to 3, and a conjugate connected thereto; Preferably, the conjugate comprises a solid phase carrier; Preferably, the solid phase carrier is magnetic particles.
8. Use of the CENPA fusion antigen according to any one of claims 1 to 4, the biomaterial according to claim 5, or the polypeptide conjugate according to claim 7 in the preparation of a product for detecting CENPA antibodies.
9. A kit for detecting CENPA antibodies, characterized in that: Comprising at least one of the CENPA fusion antigen according to any one of claims 1 to 4, the biomaterial according to claim 5, and the polypeptide conjugate according to claim 7; Preferably, the amino acid sequence of the CENPA fusion antigen is as shown in SEQ ID NO.1 or 2.
10. A method for detecting CENPA antibodies for non-diagnostic purposes, characterized in that: include: The sample to be tested is brought into contact with the CENPA fusion antigen coated on a solid phase carrier, and the CENPA antibody captured by the CENPA fusion antigen is recognized by the labeled antibody.
Citation Information
Patent Citations
Carrier protein His6-H4-NLS-Tat-AHNP and preparation method
CN105732819A
Centromere / kinetochore protein genes for cancer diagnosis, prognosis and treatment selection
CN106661624A
Modified centromere protein as well as preparation method, biological material and application of modified centromere protein
CN115925991A
Fusion proteins and methods thereof
WO2016105517A1
Bispecific autoantigen-immune effector cell engaging antibodies and uses thereof
WO2024124155A1
Cited By
Polyclonal antibody of porcine CENP-A protein as well as preparation method and application of polyclonal antibody
CN120485197A
